aInstitut Pasteur, Emerging Diseases Epidemiology Unit, Paris bINSERM U1018, Centre de Recherche en Epidémiologie et Santé des Populations, Le Kremlin-Bicêtre cFaculté de Médecine Paris Sud, Université Paris Sud, Paris dDepartment of Public Health, AP-HP, Bicêtre Hospital, Le Kremlin-Bicêtre, France eMedical Research Council, Clinical Trials Unit, London, UK fCluster Infectious Diseases, Department of Research, Center for Infection and Immunity Amsterdam (CINIMA), Public Health Service, Amsterdam, The Netherlands gResearch Department of Infection and Population Health, UCL Medical School, London, UK hSan Paolo Hospital, Milan, Italy iInternational AIDS Vaccine Initiative, San Francisco, USA jRobert Koch Institut, Berlin, Germany kUlleval Hospital, Oslo, Norway lINSERM U1012, Le Kremlin-Bicêtre mDepartment of Internal Medicine, AP-HP, Bicêtre Hospital, Le Kremlin-Bicêtre nUniversité Paris-Sud, Paris, France.
AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01.
HIV-controllers spontaneously maintain HIV viremia at an undetectable level. We aimed to describe the delay to control from seroconversion, the duration of control, and risk factors for losing control.
HIV-controllers were identified from a pooled dataset of 24 seroconverter cohorts from Europe, Australia, and Canada (CASCADE). HIV-controllers had at least five consecutive viral loads less than 400/500 copies/ml, while antiretroviral therapy naive, for at least 5 years after seroconversion. End of control was defined as two consecutive viral loads above 2000 copies/ml. Duration of control was described using Kaplan-Meier estimates; factors associated with duration of control were identified using a Cox model. CD4⁺ cell count evolution during control was described using a mixed model.
Of 9896 eligible seroconverters, we identified 140 (1.4%) HIV-controllers, the largest database of HIV-controllers followed from seroconversion. For 64 with viral load measured within 24 months from seroconversion, median delay to control was 16.7 (interquartile range: 7.8-37.9) months. Probability of maintaining control 20 years after seroconversion was 0.74 [95% confidence interval (CI): 0.64-0.85]. Occurrence of blips followed by return to undetectability did not increase the risk of loss of control [hazard ratio: 0.81 (95% CI: 0.10-6.70)]. However, CD4⁺ cell loss during control was significantly accelerated in individuals with blips.
In most individuals, control occurred rapidly after seroconversion; however, more than 3 years were required to achieve control in 25% of HIV-controllers. Control may be sustained even when CD4⁺ cell levels are below 500 cells/μl, opening important new perspectives to understand the physiopathology underlying control.
HIV 感染者能够自发地将 HIV 病毒载量维持在不可检测的水平。本研究旨在描述从血清转换到获得病毒学控制的时间延迟、控制的持续时间以及失去控制的风险因素。
本研究中的 HIV 感染者是从欧洲、澳大利亚和加拿大的 24 个血清转换队列的汇总数据集(CASCADE)中确定的。这些 HIV 感染者在血清转换后至少 5 年,且未接受过抗病毒治疗,至少连续 5 次病毒载量低于 400/500 拷贝/ml。控制终点定义为两次连续的病毒载量超过 2000 拷贝/ml。采用 Kaplan-Meier 估计描述控制的持续时间;采用 Cox 模型识别与控制持续时间相关的因素。采用混合模型描述控制期间 CD4⁺细胞计数的变化。
在 9896 名符合条件的血清转换者中,我们确定了 140 名(1.4%)HIV 感染者,这是从血清转换开始以来对 HIV 感染者进行的最大规模的数据库随访。对于 64 名在血清转换后 24 个月内进行病毒载量测量的感染者,获得控制的中位时间延迟为 16.7(四分位间距:7.8-37.9)个月。血清转换后 20 年维持控制的概率为 0.74[95%置信区间(CI):0.64-0.85]。发生回升后再次回到不可检测水平的病毒学突破并不增加控制失败的风险[风险比:0.81(95%CI:0.10-6.70)]。然而,控制期间 CD4⁺细胞丢失在发生病毒学突破的个体中明显加速。
在大多数个体中,控制在血清转换后迅速发生;然而,仍有 25%的 HIV 感染者需要 3 年以上才能获得控制。即使 CD4⁺细胞水平低于 500 个/μl,控制也可能持续,这为理解控制的病理生理学提供了新的重要视角。